» Articles » PMID: 22150162

Cancer Risk Among Patients with Systemic Sclerosis: a Nationwide Population Study in Taiwan

Overview
Publisher Informa Healthcare
Specialty Rheumatology
Date 2011 Dec 14
PMID 22150162
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Systemic sclerosis (SSc) has been associated with high cancer risk. We compared the cancer risk among SSc patients with that among the general Taiwanese population.

Methods: The catastrophic illness registry of the Taiwan National Health Insurance Research Dataset (NHIRD) was used to identify patients diagnosed with SSc and cancer in Taiwan during 1996-2008. The standardized incidence ratio (SIR) for cancer was calculated, and mortality was ascertained using the data from the National Death Registry.

Results: Data analysis revealed that 2053 (472 men, 1581 women) Taiwanese individuals were diagnosed with SSc during the study period and 83 (30 men, 53 women) had cancer. The incidence of cancer was 6.9/1000 person-years. The most common cancer sites in male SSc patients were the lung (n = 10), oral cavity and pharynx (n = 8), and gastrointestinal tract (n = 4), and those in female patients were the breast (n = 11), lungs (n = 11), and blood (n = 6). Compared to the Taiwanese population of 1996, the all-cancer SIR for SSc was 1.63 [95% confidence interval (CI) 1.31-2.01]. Cancer risk was elevated for cancers of the lung (SIR 4.20), oral cavity and pharynx (SIR 3.67), and blood (SIR 3.50). A cancer diagnosis in SSc patients was associated with a hazard ratio (HR) of 2.15 (95% CI 1.30-3.53). Among cancer patients, a diagnosis of SSc was not associated with increased mortality.

Conclusions: SSc patients are at high risk of developing cancer, especially of the lung, oral cavity and pharynx, and blood.

Citing Articles

Unveiling the shared genes between systemic sclerosis and lung cancer.

Pan P, Liu X, Wang Y, Wang H, Xu C, Lu J Front Med (Lausanne). 2025; 11:1431642.

PMID: 39744538 PMC: 11688373. DOI: 10.3389/fmed.2024.1431642.


Characterizing the Links Between Systemic Sclerosis and Breast Cancer.

Dutt A, Arcinas L, Chen J, Shaikh R, Jun S, Kooner A Cureus. 2024; 16(8):e66653.

PMID: 39262545 PMC: 11390145. DOI: 10.7759/cureus.66653.


Systemic Inflammatory Disorders, Immunosuppressive Treatment and Increase Risk of Head and Neck Cancers-A Narrative Review of Potential Physiopathological and Biological Mechanisms.

Vale N, Pereira M, Amaral Mendes R Cells. 2023; 12(17).

PMID: 37681925 PMC: 10487135. DOI: 10.3390/cells12172192.


Preventative Care in Scleroderma: What Is the Best Approach to Bone Health and Cancer Screening?.

Calderon L, Domsic R, Shah A, Pope J Rheum Dis Clin North Am. 2023; 49(2):411-423.

PMID: 37028844 PMC: 10845237. DOI: 10.1016/j.rdc.2023.01.011.


Systemic Sclerosis Association with Malignancy.

Lepri G, Catalano M, Bellando-Randone S, Pillozzi S, Giommoni E, Giorgione R Clin Rev Allergy Immunol. 2022; 63(3):398-416.

PMID: 36121543 PMC: 9674744. DOI: 10.1007/s12016-022-08930-4.